- Hepatitis B vaccines prepared from yeast by recombinant DNA techniques: memorandum from a WHO meeting. Bull World Health Organ. 1985;63:57-61.
- Organization WH. Global health sector strategy on Viral hepatitis 2016–2021. Towards endingviral hepatitis, June 2016 (WHO/HIV/2016.06).
- Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20:992-1000.
- Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54:1-31.
- Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China--declining HBV prevalence due to Hepatitis B vaccination. Vaccine. 2013;31 Suppl 9:J21-28.
- Zhang L, Gui XE, Teter C, Zhong H, Pang Z, Ding L, et al. Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine. Vaccine. 2014;32:6091-6097.
- Ding Y, Sheng Q, Ma L, Dou X. Chronic HBV infection among pregnant women and their infants in Shenyang, China. Virol J. 2013;10:17.
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-725.
- Hu Y, Wu Q, Xu B, Zhou Z, Wang Z, Zhou YH. Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine. 2008;26:6064-6067.
- Wang Z, Zhang S, Luo C, Wu Q, Liu Q, Zhou YH, et al. Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine. PLoS One. 2011;6:e25130.
- Junqueira AL, Tavares VR, Martins RM, Frauzino KV, Silva AM, Rodrigues IM, et al. Presence of maternal anti-HBs antibodies does not influence hepatitis B vaccine response in Brazilian neonates. Mem Inst Oswaldo Cruz. 2011;106:113-116.
- Wang C, Wang C, Jia ZF, Wu X, Wen SM, Kong F, et al. Protective effect of an improved immunization practice of mother-to-infant transmission of hepatitis B virus and risk factors associated with immunoprophylaxis failure. Medicine (Baltimore). 2016;95:e4390.
- Marsac D, Puaux AL, Riviere Y, Michel ML. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice. Immunobiology. 2005;210:305-319.
- Devasahayam M. Factors affecting the presentation of exogenous hepatitis B virus core antigen. Indian J Exp Biol. 2007;45:689-695.
- Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother. 2010;1:87-93.
- Lu IC, Jean MC, Lin CW, Chen WH, Perng DS, Lin CW, et al. Predictive factors for anti-HBs status after 1 booster dose of hepatitis B vaccine. Medicine (Baltimore). 2016;95:e5023.
- Habib S, Shaikh OS. Hepatitis B immune globulin. Drugs Today (Barc). 2007;43:379-394.
- Zuckerman JN. Review: hepatitis B immune globulin for prevention of hepatitis B infection. J Med Virol. 2007;79:919-921.
- Hepatitis B vaccines. Wkly Epidemiol Rec. 2009;84:405-419.
- Wei KP, Zhu FC, Liu JX, Yan L, Lu Y, Zhai XJ, et al. The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study. Vaccine. 2018;36:256-263.
- Wang F, Zhang G, Zheng H, Miao N, Shen L, Wang F, et al. Post-vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers in 4 provinces of China. Vaccine. 2017;35:4229-4235.
- Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine. 1994;12:1453-1459.
- Ughachukwu P, Okonkwo P, Unekwe P, Ogama J. Effect of methylprednisolone injection on interleukin-4 and interferon-gamma expression following hepatitis B vaccination in mice. Turk J Med Sci. 2016;46:1540-1545.
- Morrey JD, Motter NE, Chang S, Fairman J. Breaking B and T cell tolerance using cationic lipid--DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV. Antiviral Res. 2011;90:227-230.
- Li Y, Chen JH, Shu XG, Chen JH, Xia QH, Yuan WZ, et al. A study of immune response to HBsAg mediated by CD4+ memory T lymphocytes in immunized HBV transgenic mice. Zhonghua Gan Zang Bing Za Zhi. 2016;24:897-901.
- Yin D, Liang W, Xing S, Gao Z, Zhang W, Guo Z, et al. Hepatitis B DNA vaccine-polycation nano-complexes enhancing immune response by percutaneous administration with microneedle. Biol Pharm Bull. 2013;36:1283-1291.
- Yang YJ, Liu CC, Chen TJ, Lee MF, Chen SH, Shih HH, et al. Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. Pediatr Infect Dis J. 2003;22:584-588.
- Pongpipat D, Suvatte V, Assateerawatts A. Hepatitis B immunization in high risk neonates born from HBsAg positive mothers: comparison between plasma derived and recombinant DNA vaccine. Asian Pac J Allergy Immunol. 1989;7:37-40.
- Duval B, Gilca V, Boulianne N, De Wals P, Masse R, Trudeau G, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J. 2005;24:213-218.
- Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis. 1999;179:1319-1325.
- Weeratna RD, Brazolot Millan CL, McCluskie MJ, Siegrist CA, Davis HL. Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol Med Microbiol. 2001;30:241-247.
- Schillie S, Murphy TV, Sawyer M, Ly K, Hughes E, Jiles R, et al. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep. 2013;62:1-19.
- Siegrist CA. Neonatal and early life vaccinology. Vaccine. 2001;19:3331-3346.
- Agladioglu S, Beyazova U, Camurdan AD, Sahin F, Atak A. Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules. Infection. 2010;38:269-273.
- Cáceres VM, Strebel PM, Sutter RW. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis. 2000;31:110-119.
- Masters NB, Wagner AL, Ding Y, Zhang Y, Boulton ML. Assessing measles vaccine failure in Tianjin, China. Vaccine. 2019;37:3251-3254.
- Al Mahtab M. Elimination of Hepatitis Viruses: Bangladesh Scenario. Euroasian J Hepatogastroenterol. 2017;7:40-42.
|